Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 1 - 15 of 17
Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers. Transcript So, I wanted to talk to you today about pleural effusions. Pleural effusions — it’s a complex term, and it’s a very common problem, so
Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE). Transcript With the pleural fluid that’s built up around the lung — this fluid that exist in between the linings, or as we discussed
A tunneled pleural catheter is an excellent way to manage the symptoms of a recurrent malignant pleural effusion. Dr. Jed Gorden describes how it is placed and how it works. Transcript So we’re talking today about pleural fluid — fluid that resides around the lung, in-between this space that we’re
Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE). Transcript So we’re talking today about pleural fluid, the fluid that builds up around the lung — fluid that causes people be short of breath, often have symptoms like cough
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank
Dr. Sandip Patel, Associate Professor of Medicine at the Moores Cancer Center, UC San Diego Health, joined GRACE to offer updates to our Lung Cancer Video Library. In this video, Dr. Patel discusses the current status of tumor mutation burden. We thank the following organizations for their support
For this addition to the Lung Cancer Video Library, Dr. Millie Das joins GRACE to discuss current updates in treatment options for non small cell lung cancer. In this video, Dr. Das discusses the current leading treatment options for patients with low or negative tumor PDL1 expression and advanced
For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates in treatments for non small cell lung cancer. In this video, Dr. Bauml discusses updated information on emerging molecular targets in nsclc - RET fusions. To join the conversation
For this new addition to the GRACE Lung Cancer Video Library, Dr. Josh Bauml joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Bauml discusses updated information on emerging molecular targets in nsclc - MET. To join the conversation, visit https://cancergrace
For this new addition to the GRACE Lung Cancer Video Library, Dr. Sandip Patel joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Patel discusses updated information on emerging molecular targets in nsclc - KRAS. To join the conversation, visit https:/
For this new addition to the GRACE Lung Cancer Video Library, Dr. Sandip Patel joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Patel discusses updated information on emerging molecular targets in nsclc - EGFR Exon 20. To join the conversation, visit https:/
For this new addition to the GRACE Lung Cancer Video Library, Dr. Stephen Liu joins GRACE to discuss current updates in non small cell lung cancer. In this video, Dr. Liu discusses updated information on the leading treatment options for patients with negative tumor pd l1. To join the conversation